Spots Global Cancer Trial Database for Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Study Description

Brief Summary: A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma. The study will include an intra-patient dose escalation phase, followed by a dose expansion phase.

Detailed Description: This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 50 patients. The study will consist of 2 phases: an intra-patient dose escalation phase, followed by a dose exposure phase. A safety review will be completed by the Data Review Committee after every dose in every patient in the dose escalation phase to review pharmacokinetics, safety and tolerability data. In the exposure part of the study, up to 30 additional patients will be recruited and treated at increased dose exposure to better characterize drug safety, tolerability, and preliminary efficacy.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial